Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-03-03 4:30 pm Sale | 13D | Marker Therapeutics, Inc. MRKR | Aisling Capital IV LP | 464,285 5.46% | -3,035,715 (-86.73%) | View |
| 2023-02-08 5:00 pm Purchase | 13G | Elevation Oncology, Inc. ELEV | Aisling Capital IV LP | 2,876,561 12.34% | 10,413 (+0.36%) | View |
| 2022-02-14 12:16 pm Purchase | 13G | Elevation Oncology, Inc. ELEV | Aisling Capital IV LP | 2,866,148 12.33% | 2,866,148 (New Position) | View |
| 2022-02-14 12:14 pm Sale | 13G | Viracta Therapeutics, Inc. VIRX | Aisling Capital IV LP | 288,571 0.77% | -9,811,429 (-97.14%) | View |
| 2019-07-15 4:15 pm Purchase | 13G | SUNESIS PHARMACEUTICALS INC SNSS | Aisling Capital IV LP | 10,100,000 10% | 2,500,000 (+32.89%) | View |
| 2019-02-05 4:06 pm Sale | 13G | Protagonist Therapeutics, Inc. PTGX | Aisling Capital IV LP | 0 0% | -1,015,761 (Position Closed) | View |
| 2019-01-24 5:21 pm Purchase | 13G | SUNESIS PHARMACEUTICALS INC SNSS | Aisling Capital IV LP | 7,600,000 12.6% | 4,625,000 (+155.46%) | View |
| 2018-10-19 5:09 pm Purchase | 13D | Marker Therapeutics, Inc. MRKR | Aisling Capital IV LP | 3,500,000 7.7% | 3,500,000 (New Position) | View |